Duke–NUS Medical School

Singapore to host the 7th World One Health Congress

Retrieved on: 
Wednesday, October 26, 2022
Epidemiology, Congress, Bill, Medicine, Joint Institute for Nuclear Research, Zoonosis, Pandemic, World Bank, Policy, Education, Republic, One Health, Health, Patient, WOHC, Private sector, Twitter, World, Health equity, Research, Duke–NUS Medical School, Knowledge, Learning, Public health, Food safety, Convention center, World Health Organization, Kathrin Glock, SingHealth, Head, Global health, Opening ceremony, COVID-19, AMC, Temasek Foundation, Pharmaceutical industry, Tutoring, Science, Facebook

SINGAPORE, Oct. 26, 2022 /PRNewswire/ -- The 7th World One Health Congress (WOHC), the world's premier event to advance the One Health agenda, will take place in Singapore at the iconic Sands Expo and Convention Centre, Marina Bay Sands, from 7 to 11 November 2022. Mdm Halimah Yacob, President of the Republic of Singapore, will grace the event's Opening Ceremony on 7 November as its Guest-of-Honour and deliver the Opening Address.

Key Points: 
  • SINGAPORE, Oct. 26, 2022 /PRNewswire/ --The 7th World One Health Congress (WOHC), the world's premier event to advance the One Health agenda, will take place in Singapore at the iconic Sands Expo and Convention Centre, Marina Bay Sands, from 7 to 11 November 2022.
  • The Director-General of the World Health Organization, Dr Tedros Adhanom Ghebreyesus, and the Director-General of the World Organisation for Animal Health, Dr Monique Eloit, will deliver opening remarks on the first day.
  • "The 7th World One Health Congress will host important conversations and promote integrated regional and global efforts that are essential to prevent, predict, prepare and respond to crises and safeguard our planet's healthy and sustainable future.
  • The SingHealth Duke-NUS Global Health Institute is pleased to represent Singapore in organising this Congress, and play a part in advancing global efforts to improve health outcomes and achieve health equity for all."

Singapore to host the 7th World One Health Congress

Retrieved on: 
Wednesday, October 26, 2022
Epidemiology, Congress, Bill, Medicine, Joint Institute for Nuclear Research, Zoonosis, Pandemic, World Bank, Policy, Education, Republic, One Health, Health, Patient, WOHC, Private sector, Twitter, World, Health equity, Research, Duke–NUS Medical School, Knowledge, Learning, Public health, Food safety, Convention center, World Health Organization, Kathrin Glock, SingHealth, Head, Global health, Opening ceremony, COVID-19, AMC, Temasek Foundation, Pharmaceutical industry, Tutoring, Science, Facebook

SINGAPORE, Oct. 26, 2022 /PRNewswire/ -- The 7th World One Health Congress (WOHC), the world's premier event to advance the One Health agenda, will take place in Singapore at the iconic Sands Expo and Convention Centre, Marina Bay Sands, from 7 to 11 November 2022. Mdm Halimah Yacob, President of the Republic of Singapore, will grace the event's Opening Ceremony on 7 November as its Guest-of-Honour and deliver the Opening Address.

Key Points: 
  • SINGAPORE, Oct. 26, 2022 /PRNewswire/ --The 7th World One Health Congress (WOHC), the world's premier event to advance the One Health agenda, will take place in Singapore at the iconic Sands Expo and Convention Centre, Marina Bay Sands, from 7 to 11 November 2022.
  • The Director-General of the World Health Organization, Dr Tedros Adhanom Ghebreyesus, and the Director-General of the World Organisation for Animal Health, Dr Monique Eloit, will deliver opening remarks on the first day.
  • "The 7th World One Health Congress will host important conversations and promote integrated regional and global efforts that are essential to prevent, predict, prepare and respond to crises and safeguard our planet's healthy and sustainable future.
  • The SingHealth Duke-NUS Global Health Institute is pleased to represent Singapore in organising this Congress, and play a part in advancing global efforts to improve health outcomes and achieve health equity for all."

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, June 22, 2022
Health, Infectious Diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Messenger RNA, RNA, Patent, Therapy, COVID-19, Risk, Safety, Annual report, III, Janssen Pharmaceuticals, Vaccine, Director, Liver, Cystic fibrosis, Cystic Fibrosis Foundation, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Company, OTC, Takeda Pharmaceutical Company, LinkedIn, Glycogen storage disease type III, MicroRNA, Private Securities Litigation Reform Act, Hepatitis B virus, Financial compensation, DNA, Fatty liver disease, ARCT, Severe acute respiratory syndrome coronavirus 2, Gene editing, Intention, SEC, CureVac, Nasdaq, NASH, Twitter, Infection, Employment, Duke–NUS Medical School, Johnson & Johnson, RNA transfection, Arcturus

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $12.26 per share, the closing price of the Companys common stock as reported by Nasdaq on June 16, 2022.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

A New T-Cell activation assay based on Hyris qPCR Technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity

Retrieved on: 
Wednesday, June 15, 2022
Antibody, Doctor of Philosophy, Solution, European Review for Medical and Pharmacological Sciences, Population, Infection, COVID-19, Omicron, Vaccine, Technology, CXCL10, CEO, Nephrology, Research, Peptide, Manuscript, Disease, Severe acute respiratory syndrome coronavirus 2, Molecular biology, ELISpot, Death, Pathology, Assistant, Duke–NUS Medical School, Degenerative disease, PCR, Italy, GLOBE, RNA transfection, Pharmaceutical industry, Nature Biotechnology, Medicine, Genetics

With more than 10 billion total vaccine doses administered worldwide, vaccination campaigns have already started to attenuate this global crisis .

Key Points: 
  • With more than 10 billion total vaccine doses administered worldwide, vaccination campaigns have already started to attenuate this global crisis .
  • In order to maximize vaccine effectiveness, the efficacy and duration of protective immunity will need to be systematically assessed and monitored as widely as possible.
  • A team of internationally renowned medical scientists recently published a related paper in Nature Biotechnology , addressing the efficacy and sensitivity of a new type of assay to detect SARS-CoV-2 cellular immunity.
  • "Both the humoral (antibodies) and cellular immune response act in coordination to achieve long-term protection from viral infections.

Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022

Retrieved on: 
Monday, June 13, 2022
SingHealth, Company, Conference, Marketing, CD30, Lymphatic system, European Medicines Agency, TT11, PRIME, Hematological Cancer Research Investment and Education Act, Cancer, Therapy, FDA, GLOBE, Private Securities Litigation Reform Act, Trial of the century, Duke–NUS Medical School, Hodgkin lymphoma, Immunotherapy, Associate professor, Safety, NCCS, Pharmaceutical industry, Medical device

SINGAPORE, June 13, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.

Key Points: 
  • SINGAPORE, June 13, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.
  • Tessas scientific session will focus on CD30 CAR-T targeting of CD30+ lymphomas and will feature a presentation from Dr. Ivan Horak, Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics.
  • Tessa is currently advancing two clinical programs leveraging distinct CD30 CAR-T technologies for the treatment of CD30+ lymphomas.
  • Additionally, Tessa is developing an allogenic off-the-shelf CD30-CAR EBVST cell therapy TT11X targeting relapsed or refractory CD30-positive lymphomas.

Evecxia Therapeutics Announces Leadership Transition to Support Next Phase of Development and Growth

Retrieved on: 
Monday, June 13, 2022
Biotechnology, Pharmaceutical, Health, Mental Health, Faculty, Biotechnology, Lists of diseases, Biomedical sciences, Research Triangle Park, National University of Singapore, University, Bristol Myers Squibb, Senior, Duke University, List of life sciences, School, National university, Therapy, Duke–NUS Medical School, Growth, Patient, Brain, Doctor of Philosophy, Acquisition, National University Hospital, Research and development, Drug development, NTU, University of Alabama at Birmingham School of Medicine, 5-Hydroxytryptophan, Nanyang Technological University, Technology, Management, Pharmaceutical industry, Biochemistry, Microbiology

We are delighted to have Dr. Patti join Evecxia at this exciting stage of development.

Key Points: 
  • We are delighted to have Dr. Patti join Evecxia at this exciting stage of development.
  • Joe is a seasoned drug development executive with a proven track record in leading both private and public biopharmaceutical companies and generating significant shareholder value, said Thomas H. Aasen, independent board member of Evecxia.
  • We believe he has an ideal combination of experience and leadership skills to advance Evecxia to the next level of development and growth.
  • Evecxia Therapeutics is a privately funded, clinical stage pharmaceutical company, located in Research Triangle Park, NC.

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Saturday, May 21, 2022
Other Health, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, FDA, Health, Employment, Severe acute respiratory syndrome coronavirus 2, RNA transfection, DNA, Company, Private Securities Litigation Reform Act, Cystic Fibrosis Foundation, NASH, Duke–NUS Medical School, Nasdaq, Messenger RNA, Cystic fibrosis, ARCT, Vaccine, OTC, Gene editing, Financial compensation, Liver, CureVac, COVID-19, Fatty liver disease, Patent, Johnson & Johnson, Takeda Pharmaceutical Company, Intention, Janssen Pharmaceuticals, Infection, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., RNA, III, Safety, Glycogen storage disease type III, MicroRNA, Hepatitis B virus, LinkedIn, Twitter, Therapy, SEC, Director, Risk, Annual report, Arcturus

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $16.84 per share, the closing price of the Companys common stock as reported by Nasdaq on May 16, 2022.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention

Retrieved on: 
Tuesday, May 24, 2022
Research and development, Pain, Traffic barrier, Company, Organic acid, Duke–NUS Medical School, MFSD2A, Doctor of Philosophy, Lists of diseases, Therapy, Epilepsy, BIO, CNS, BBB, San Diego Convention Center, Anxiety, Central nervous system, Multiple sclerosis, Development, CA, Medical device, Research, MD

The presentation will take place on Monday, June 13, 2022 at 12:30 PM PDT in Theater 2 in the San Diego Convention Center.

Key Points: 
  • The presentation will take place on Monday, June 13, 2022 at 12:30 PM PDT in Theater 2 in the San Diego Convention Center.
  • "We have made tremendous progress on development of the Travecta platform and pipeline programs thus far in 2022," noted Dr. Manning.
  • "BIO is an excellent opportunity to share this progress as we move our lead program toward the clinic by the end of the year."
  • Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the BBB.

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

Retrieved on: 
Monday, May 9, 2022
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Cystic fibrosis, Private Securities Litigation Reform Act, Messenger RNA, Nasdaq, Twitter, CureVac, RNA, Safety, Janssen Pharmaceuticals, HBV, Johnson & Johnson, Glycogen storage disease type III, COVID, Trial of the century, Duke–NUS Medical School, OTC, Gene editing, III, Risk, Annual report, GSD, Therapy, Patent, DNA, Cystic Fibrosis Foundation, Severe acute respiratory syndrome coronavirus 2, Vaccine, LinkedIn, Intention, NASH, Fatty liver disease, Takeda Pharmaceutical Company, SEC, RNA transfection, Hepatitis B virus, ARCT, MicroRNA, Arcturus

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, self-amplifying mRNA, small interfering RNA, circular RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, self-amplifying mRNA, small interfering RNA, circular RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (with patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.
  • All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Retrieved on: 
Thursday, May 5, 2022
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Cystic fibrosis, Private Securities Litigation Reform Act, Omicron, Nasdaq, Messenger RNA, Twitter, CureVac, RNA, Company, MicroRNA, Time, Janssen Pharmaceuticals, HBV, Johnson & Johnson, Glycogen storage disease type III, COVID, Duke–NUS Medical School, Clinical trial, OTC, Gene editing, MNT, III, Risk, Annual report, GSD, Therapy, Patent, CRO, DNA, D614G, Multimedia, Cystic Fibrosis Foundation, Severe acute respiratory syndrome coronavirus 2, Beta, Vaccine, Arcturus Therapeutics, LinkedIn, Intention, NASH, Infection, Fatty liver disease, Liver, Takeda Pharmaceutical Company, SEC, Vaccination, RNA transfection, CEO, Hepatitis B virus, ARCT, Interval (mathematics), Arcturus, Infectious Diseases, Pharmaceutical, Health, Clinical Trials

These results provide additional validation of Arcturus next generation STARR mRNA technology for vaccines.

Key Points: 
  • These results provide additional validation of Arcturus next generation STARR mRNA technology for vaccines.
  • Samples from the trial will be further analyzed for neutralizing antibody activity against different strains of SARS-CoV-2, including the Omicron lineage.
  • The Company has initiated start-up activities with an international CRO toward a pivotal Phase 3 booster trial intended to support global registration.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.